How much revenue does Hinova Pharmaceuticals make?

Hinova Pharmaceuticals reported 20.47 million CNY in revenue for fiscal year 2025, up 5480.1% from 366,840 CNY in fiscal year 2024. In Q1 2026 revenue was 26.03 million CNY.

Where does Hinova Pharmaceuticals make most of its revenue?

China: 100% of revenue by region in fiscal year 2025, followed by Overseas (under 1%).

What companies are similar to Hinova Pharmaceuticals?

Listed companies of a similar size in the same industry (additional cancer treatment drugs) include Jiangsu Yahong Meditech Co., Ltd. (688176.SS), Sichuan Huiyu Pharmaceutical Co., Ltd. (688553.SS), Shouyao Holdings (Beijing) Co., Ltd. (688197.SS).

Hinova Pharmaceuticals Inc. (688302.SS) Stock

About Hinova Pharmaceuticals Inc.

Hinova Pharmaceuticals Inc., a clinical-stage pharmaceutical company, develops and produces therapeutics for cancers and metabolic syndromes. Its core product is Hainaan, a deuterium enzalutamide soft capsules for the treatment of prostate cancer; it also develops drugs based on proteolysis targeting chimera and deuteration technology. The company's products pipeline includes HP518, a PROTAC molec...

At a glance

Hinova Pharmaceuticals reported revenue of 20.47 million CNY for fiscal year 2025, up 5480.1% from fiscal year 2024, and net income of -137.25 million CNY. In Q1 2026 (the quarter ended March 31, 2026) revenue was 26.03 million CNY. China was its largest region in fiscal year 2025, with 100% of revenue.

Figures from company filings; latest fiscal year ended December 31, 2025.

No profile data available.

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.